Introduction {#section6-1179544118773068}
============

Osteoarthritis (OA) is the most common arthritis worldwide causing pain and impairment in physical function.^[@bibr1-1179544118773068]^ Intra-articular hyaluronan (IA-HA) injections are believed to exert their therapeutic benefit by providing chondroprotection and anti-inflammatory effects, stimulating endogenous proteoglycan and HA synthesis, limiting subchondral bone changes, and reducing the activity of joint nociceptors, in addition to its mechanical benefit of lubricating the joint.^[@bibr2-1179544118773068],[@bibr3-1179544118773068]^ In the United States, IA-HA preparations approved for treatment of the pain of knee OA have been widely used for almost 20 years.^[@bibr4-1179544118773068],[@bibr5-1179544118773068]^ Despite the reported efficacy and safety of IA-HA injections and experience in clinical practice and the recommendation by American Medical Society for Sport Medicine (AMSSM),^[@bibr6-1179544118773068]^ recent OA treatment guidelines by the American Academy of Orthopedic Surgeons (AAOS) and the American College of Rheumatology (ACR) have queried their therapeutic utility.^[@bibr7-1179544118773068][@bibr8-1179544118773068]--[@bibr9-1179544118773068]^

Gel-200 (Gel-One^®^; Seikagaku Corporation, Tokyo, Japan) is a sterile, transparent, and viscoelastic hydrogel composed of a cross-linked HA, a derivative of a highly purified HA product approved by the US Food and Drug Administration (FDA) in 2011 for treatment of pain of OA in the knee. There are 3 randomized controlled trials (RCTs) separately conducted in the United States. The safety and effectiveness of single and repeated injections of Gel-200 was demonstrated over 13 weeks (Study SI-6606/01 and Study Gel/1132).^[@bibr10-1179544118773068][@bibr11-1179544118773068]--[@bibr12-1179544118773068]^ In the 26-week RCT (Study Gel/1133), the efficacy over 26 weeks of a single injection of Gel-200 was demonstrated based on a noninferiority analysis compared with currently approved 3 weekly injections of IA-HA products that contributed to the FDA approval for efficacy over 26 weeks.^[@bibr13-1179544118773068]^ These RCTs have common efficacy measurements; however, there are difference in randomization allocations, statistical analyses approaches, and the primary endpoints in each RCT.

Following a single injection, 3 IA-HA products marketed in the United States are indicated for 26-week efficacy; labeling for 2 products report only single clinical trial results in detail.^[@bibr11-1179544118773068],[@bibr13-1179544118773068][@bibr14-1179544118773068]--[@bibr15-1179544118773068]^

To provide further clinical details of the 26-week efficacy and safety of a single injection of Gel-200 using common efficacy measurements and statistical analysis tests, we assessed the efficacy and safety of Gel-200 over 26 weeks following a single injection using established outcome measures by pooling data from 2 available RCTs with Gel-200 (SI-6606/01 and Gel/1133) with similar study designs and common efficacy measures.

Methods {#section7-1179544118773068}
=======

Trial design {#section8-1179544118773068}
------------

SI-6606/01 was a multi-center 13-week RCT. Patients were screened 1 to 2 weeks prior to randomization. Patients with pain \>4 weeks, Kellgrean-Lawrence (K-L) grade 1 to 3 scores by X-ray, and Western Ontario and McMaster Universities Arthritis Index (WOMAC) pain subscores ≥40 mm in the target knee were randomized to receive Gel-200 or phosphate buffered saline (PBS) in a 2:1 ratio at week 0. Patients returned for efficacy and safety evaluations at weeks 3, 6, 9, and 13 following a single injection of Gel-200 or PBS ([Figure 1](#fig1-1179544118773068){ref-type="fig"}). Efficacy measurements included WOMAC total and subscores, physician and patient global assessments of disease activity, and Outcome Measures in Rheumatology Clinical Trials and Osteoarthritis Research Society International (OMERACT-OARSI) strict responders.^[@bibr16-1179544118773068][@bibr17-1179544118773068]--[@bibr18-1179544118773068]^

![Overview of clinical studies.](10.1177_1179544118773068-fig1){#fig1-1179544118773068}

Gel/1133 was a 26-week multi-center RCT. Patients were screened 1 to 2 weeks prior to randomization. Patients randomized to Gel-200 or PBS with a 1:1 ratio at week 0 were required to have had pain \>4 weeks in the target knee, K-L grade 1 to 3 scores by X-ray, and WOMAC pain subscores of 50 to 90 mm following a 50-foot walk test. Patients returned for efficacy and safety evaluations at weeks 3, 6, 12, 18, and 26 following a single injection of Gel-200 or PBS ([Figure 1](#fig1-1179544118773068){ref-type="fig"}).

Efficacy measurements included WOMAC scores following a 50-foot walk test, physician and patient global evaluations, and OMERACT-OARSI strict responders.^[@bibr16-1179544118773068][@bibr17-1179544118773068]--[@bibr18-1179544118773068]^

Both RCTs allowed patients to take rescue of acetaminophen provided not before 24 h of scheduled visits. In SI-6606/01, patients were allowed to continue OA treatments such as nonsteroidal anti-inflammatory drugs (NSAIDS) provided they remained stable, while in Gel/1133, patients discontinued background OA treatment with exception of rescue of acetaminophen.

SI-6606/01 and Gel/1133 RCTs were both approved by a central institutional review board and registered with Clinical Trials.gov (identification numbers NTC 00449696 and NTC 01934218, respectively). Both trials were conducted in the United States from August 2006 to May 2008 for SI-6606/01 and August 2013 to February 2016 for Gel/1133.

Statistical analysis {#section9-1179544118773068}
--------------------

WOMAC pain Visual Analog Scale (VAS) subscores were the primary outcome measures of treatment efficacy and used for this pooled analysis. All analyses for efficacy used intention-to-treat (ITT) populations from the RCTs, sharing the same definition of all randomized patients who received treatment and had at least 1 post-injection visit.

The focus of the pooled analyses was WOMAC VAS scores assessed at weeks 3, 6, 9, and 13 in SI-6606/01 and at weeks 3, 6, 12, 18, and 26 in Gel/1133. Data from week 13 in SI-6606/01 and week 12 in Gel/1133 were pooled for these integrated analyses. Week 9 data were omitted from the SI-6606/01 analyses because there was no equivalent visit in the Gel/1133 trial. As data were not collected at weeks 18 and 26 in SI-6606/01, these visits were treated similar to those for subjects who withdrew early or had missing data in Gel/1133.

The primary efficacy analysis was based on changes in WOMAC pain subscores in the pooled ITT population, using longitudinal analysis to incorporate information from pain scores at scheduled time points in the 2 trials. A repeated-measures model was prespecified which expressed pain scores as a linear function of treatment, time, treatment-by-time interaction, clinically relevant covariates including baseline pain scores, and a fixed site effect.

The primary efficacy objective was tested using the null hypothesis that there were no differences in mean changes from baseline in WOMAC pain subscores between Gel-200 and PBS over 26 weeks, and group comparisons were defined as the average effect over weeks 3, 6, 12, 18, and 26. For the primary analysis, the pain measure covariate referred to the scores used in the eligibility criteria of each study which were baseline WOMAC VAS pain scores following a 50-foot walk in patients from Gel/1133 and WOMAC pain subscores in patients from SI 6606/01. This analysis was repeated for WOMAC total, physical function, and stiffness subscores; patient and physician global assessments and OMERACT-OARSI strict responders over 26 weeks as secondary analyses. OMERACT-OARSI strict responders were compared between treatment groups for weeks 6 through 26 using a generalized estimating equation (GEE) regression model.

Safety was assessed in the combined safety populations from the RCTs, which included all patients who received treatment with Gel-200 or PBS.

All analyses were post hoc and specified following database lock and unblinding for both protocols.

Results {#section10-1179544118773068}
=======

Patient population {#section11-1179544118773068}
------------------

Of the 2193 subjects screened for SI-6606/01 and Gel/1133 protocols, 1196 were randomized: 1191 subjects received treatment (653: Gel-200, 538: PBS), 1184 (99.0%) subjects (649: Gel-200, 535: PBS) were included in the combined ITT population, and 1062 (88.8%) randomized subjects completed the blinded treatment phase of both RCTs in which they were enrolled.

Demographic and baseline characteristics {#section12-1179544118773068}
----------------------------------------

Demographic characteristics of Gel-200 and PBS treatment groups were similar ([Table 1](#table1-1179544118773068){ref-type="table"}). Baseline characteristics were similar between Gel-200 and PBS treatment groups with exception of baseline WOMAC VAS pain subscores, higher in the Gel-200 group than in the PBS group (*P* = .011). There were no statistically significant differences in other parameters between Gel-200 and PBS treatment groups.

###### 

Baseline characteristics and demographics.

![](10.1177_1179544118773068-table1)

  Parameter                                      PBS (N = 535)   Gel-200 (N = 649)
  ---------------------------------------------- --------------- -------------------
  Gender                                                         
   Male                                          224 (41.9)      281 (43.3)
   Female                                        311 (58.1)      368 (56.7)
  Age, years (mean ± SD)                         60.0 ± 9.47     59.9 ± 9.60
  K-L grade                                                      
   Grade 1                                       129 (24.1)      134 (20.6)
   Grade 2                                       211 (39.4)      255 (39.3)
   Grade 3                                       195 (36.4)      260 (40.1)
  Body mass index, kg/m^2^ (mean ± SD)           28.8 ± 3.90     28.5 ± 4.17
  Baseline WOMAC pain subscore, mm (mean ± SD)   61.89 ± 15.51   64.22 ± 15. 89

Abbreviations: K-L, Kellgrean-Lawrence; WOMAC, Western Ontario and McMaster Universities Arthritis Index.

No statistically significant differences were identified between treatment groups.

Primary efficacy {#section13-1179544118773068}
----------------

[Table 2](#table2-1179544118773068){ref-type="table"} summarizes analyses of changes from baseline in WOMAC pain subscores in the pooled ITT population. Treatment group differences in mean (95% confidence interval \[CI\]) changes from baseline over 26 weeks were −3.0 (−5.4 to −0.5), statistically significant (*P* = .017). Statistically significant differences were also evident for most individual time points except weeks 3 and 26.

###### 

Change from baseline in WOMAC pain subscores.

![](10.1177_1179544118773068-table2)

  Time points     Group     Estimated changes from baseline, mm   Differences, mm   95% CI         *P* value
  --------------- --------- ------------------------------------- ----------------- -------------- -----------
  Over 26 weeks   Gel-200   −23.8                                 −3.0              −5.4 to −0.5   .017
  PBS             −20.8                                                                            
  At 3 weeks      Gel-200   −22.3                                 −2.6              −5.3 to 0.1    .055
  PBS             −19.6                                                                            
  At 6 weeks      Gel-200   −24.8                                 −2.9              −5.7 to −0.0   .049
  PBS             −22.0                                                                            
  At 12 weeks     Gel-200   −24.7                                 −2.9              −5.8 to −0.0   .047
  PBS             −21.8                                                                            
  At 18 weeks     Gel-200   −25.1                                 −3.6              −6.7 to −0.4   .026
  PBS             −21.6                                                                            
  At 26 weeks     Gel-200   −22.1                                 −3.0              −6.2 to 0.2    .069
  PBS             −19.1                                                                            

Abbreviations: WOMAC, Western Ontario and McMaster Universities Arthritis Index; CI, confidence interval; PBS, phosphate buffered saline.

Secondary efficacy {#section14-1179544118773068}
------------------

[Table 3](#table3-1179544118773068){ref-type="table"} summarizes changes from baseline in other WOMAC subscores in the pooled ITT population. Treatment group differences in mean (95% CI) changes from baseline over 26 weeks in WOMAC physical function subscores were −2.1 (−4.6 to 0.4); in WOMAC stiffness subscores, −2.7 (−5.2 to −0.2); and in WOMAC total scores, −2.1 (−4.5 to 0.3). The strict OMERACT-OARSI responders were statistically significantly higher at 26 weeks with Gel-200 than with PBS (*P* = .037; [Table 4](#table4-1179544118773068){ref-type="table"}).

###### 

Changes from baseline in secondary endpoints over 26 weeks.

![](10.1177_1179544118773068-table3)

  Measurements                  Group     Estimated change from baseline, mm   Difference, mm   95% CI         *P* value
  ----------------------------- --------- ------------------------------------ ---------------- -------------- -----------
  WOMAC function                Gel-200   −22.9                                −2.1             −4.6 to 0.4    .096
  PBS                           −20.8                                                                          
  WOMAC stiffness               Gel-200   −23.4                                −2.7             −5.2 to −0.2   .036
  PBS                           −20.7                                                                          
  WOMAC total                   Gel-200   −22.8                                −2.1             −4.5 to 0.3    .091
  PBS                           −20.7                                                                          
  Physician global evaluation   Gel-200   −21.9                                −0.9             −3.2 to 1.3    .411
  PBS                           −20.9                                                                          
  Patient global evaluation     Gel-200   −18.3                                −2.7             −5.4 to −0.1   .043
  PBS                           −15.6                                                                          

Abbreviations: WOMAC, Western Ontario and McMaster Universities Arthritis Index; PBS, phosphate buffered saline.

###### 

Summary of OMERACT-OARSI strict responders.

![](10.1177_1179544118773068-table4)

            Responder, No. (%)   Odds ratio over 26 weeks                   
  --------- -------------------- -------------------------- --------------- ------
  Week 6    272 (43.2)           215 (41.2)                 1.2 (1.0-1.5)   .037
  Week 12   265 (42.3)           210 (40.9)                                 
  Week 18   167 (44.2)           153 (40.0)                                 
  Week 26   146 (39.9)           134 (36.1)                                 

Abbreviations: OMERACT-OARSI, Outcome Measures in Rheumatology Clinical Trials and Osteoarthritis Research Society International; PBS, phosphate buffered saline; CI, confidence interval.

When odds ratio \>1, then in favor of Gel-200.

Safety {#section15-1179544118773068}
------

The rates of AEs and device-related AEs were similar without statistically significant differences between Gel-200 and PBS groups ([Table 5](#table5-1179544118773068){ref-type="table"}). All serious AEs were judged unrelated to study treatment in each RCT.

###### 

Overall summary of AEs.

![](10.1177_1179544118773068-table5)

                                             Gel-200 (N = 653)   PBS (N = 538)                
  ------------------------------------------ ------------------- --------------- ------------ -----
  Total AEs                                  356 (54.5)          902             278 (51.7)   637
  Serious AEs                                15 (2.3)            26              6 (1.1)      7
  Related AEs                                92 (14.1)           163             60 (11.2)    100
  Related AEs occurring in ≥5% of patients                                                    
   Joint swelling                            103 (15.8)          125             78 (14.5)    87
   Joint effusion                            88 (13.5)           103             62 (11.5)    74
   Arthralgia                                87 (13.3)           107             57 (10.6)    72

Abbreviation: AEs, adverse events.

Discussion {#section16-1179544118773068}
==========

RCTs of Gel-200 evaluated responses at 13 and 26 weeks following a single injection of Gel-200. We focused on the efficacy of Gel-200 for treatment of knee OA pain over 26 weeks by comparing Gel-200 with PBS using pooled data from 2 well-controlled RCTs using all available clinical evidence, rather than individual clinical trial data.

Pooled analyses demonstrated that a single injection of Gel-200 resulted in statistically significant mean changes from baseline in WOMAC pain subscores compared with a single injection of PBS over 26 weeks (*P* = .017). Although measurements are different between the reported efficacy at 26 weeks by noninferiority analysis^[@bibr13-1179544118773068]^ and this pooled analysis, the efficacy of Gel-200 was demonstrated in both analyses. At 12 weeks, a statistically significant difference was evident in both the SI-6606/01 trial and the pooled analyses. These results at 2 time points support the clinical correlations of pain responses between the 2 trials. Although the primary endpoints between the 2 trials were different, the eligibility criteria, baseline characteristics, and demographics in each study were very similar except the baseline WOMAC pain subscores. Patients were randomly allocated into Gel-200 or PBS in each RCT. Pain eligibility score was not considered with WOMAC pain subscores in Gel/1133, where eligibility was the WOMAC pain score following 50-foot walk test. This might account for the difference between treatment groups in baseline WOMAC pain subscores.

Despite the different baseline pain scores in the Gel-200 combined group, treatment with Gel-200 resulted in clinically meaningful improvements from baseline. Minimal clinically important improvements (MCID) have variously been reported as 19.9 mm on the WOMAC 100-mm pain subscore and 9.1 mm on the WOMAC function subscore for knee OA or 10 on a 100 mm VAS score.^[@bibr19-1179544118773068][@bibr20-1179544118773068]--[@bibr21-1179544118773068]^ Improvements from baseline with Gel-200 were \>20 mm in WOMAC pain subscores at every time point and WOMAC function subscores over 26 weeks. Few trials of IA-HA products have reported statistically significant benefits by WOMAC stiffness^[@bibr22-1179544118773068],[@bibr23-1179544118773068]^; yet, statistically significant improvements were evident^[@bibr10-1179544118773068]^ over 13 weeks. Our pooled analyses demonstrated improvement in stiffness with Gel-200 treatment over 26 weeks. More importantly, OMERACT-OARSI strict responders, requiring 50% and ≥20 mm improvements in either WOMAC pain or function, a more stringent outcome, were statistically significant over 26 weeks.

We also pooled the safety data from 2 trials. No safety concerns were identified in the pooled data as well as the results from the individual 3 studies including those following repeat injections of Gel-200.^[@bibr10-1179544118773068][@bibr11-1179544118773068][@bibr12-1179544118773068]-[@bibr13-1179544118773068]^ Rutjes et al^[@bibr24-1179544118773068]^ reported that IA-HA treatment has a small and clinically irrelevant benefit and an increased risk for serious AEs in their systematic review. However, no evidence of increased risk of Gel-200 is identified in our safety results.

In summary, these pooled analyses provide evidence of statistically significant improvements in WOMAC pain subscores, as well as other WOMAC measures over 26 weeks following a single or repeat intra-articular injections of Gel-200 compared with PBS without major safety concerns.
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